MedTrace Logo

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-07-19

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

15mg T3D-959

Oral administration once daily in the morning

DRUG

30 mg T3D-959

Oral administration once daily in the morning

DRUG

45 mg T3D-959

Oral administration once daily in the morning

DRUG

Placebos

Oral administration once daily in the morning

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Clinilabs, Inc.

    collaborator OTHER

  • Alzheimer's Association

    collaborator OTHER

  • T3D Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Blake Swearingen, MS · T3D Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-01-20
Completion
2023-02-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251182 on ClinicalTrials.gov